1. Home
  2. ALCO vs TVGN Comparison

ALCO vs TVGN Comparison

Compare ALCO & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alico Inc.

ALCO

Alico Inc.

HOLD

Current Price

$40.03

Market Cap

297.3M

Sector

N/A

ML Signal

HOLD

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

N/A

Current Price

$6.55

Market Cap

21.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ALCO
TVGN
Founded
1960
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
297.3M
21.3M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
ALCO
TVGN
Price
$40.03
$6.55
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$44.00
N/A
AVG Volume (30 Days)
17.4K
9.1K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
N/A
EPS
1.32
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.32
$0.14
52 Week High
$45.01
$12.03

Technical Indicators

Market Signals
Indicator
ALCO
TVGN
Relative Strength Index (RSI) 53.78 55.87
Support Level $39.97 $6.22
Resistance Level $42.13 $7.42
Average True Range (ATR) 1.00 0.47
MACD 0.14 0.04
Stochastic Oscillator 39.87 74.68

Price Performance

Historical Comparison
ALCO
TVGN

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: